Pui C H, Crist W M, Look A T
Department of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101.
Blood. 1990 Oct 15;76(8):1449-63.
Virtually all cases of childhood ALL have chromosomal abnormalities and half contain translocations, which are nearly equally divided between random and nonrandom rearrangements. Nonrandom chromosomal abnormalities have been correlated with leukemic cell lineage, the degree of cell differentiation, and the specific gene involved at the molecular level. Many cytogenetic findings have prognostic significance; however, the adverse influence of certain changes, including most chromosomal translocations, may in fact be offset by the greater cytoreductive effects of intensified therapy. Table 4 summarizes the relation of selected karyotypic findings to treatment outcome in patients treated on contemporary protocols. Among all of the chromosomal abnormalities identified in childhood ALL, hyperdiploidy greater than 50 has been associated with the most favorable prognosis. At the opposite end of the spectrum, the treatment outcome for patients with classical Ph+ or hypodiploid ALL is very poor even in programs of intensive chemotherapy; alternative treatment such as bone marrow transplantation should be considered for such patients. Cases with the t(4;11)(q21;q23) also have a very poor clinical outcome, but the adverse prognosis may be limited to the infant or adolescent age groups. The prognostic significance of other nonrandom translocations, such as t(1;19)(q23;p13) and several other abnormalities, needs to be further assessed in larger numbers of patients. Finally, as more is learned about the molecular pathology underlying these rearrangements, it may be possible to develop new therapeutic agents that are specifically targeted to interfere with the aberrant gene products expressed by human leukemic cells.
几乎所有儿童急性淋巴细胞白血病(ALL)病例都存在染色体异常,其中一半含有易位,随机和非随机重排几乎各占一半。非随机染色体异常与白血病细胞系、细胞分化程度以及分子水平上涉及的特定基因相关。许多细胞遗传学发现具有预后意义;然而,某些变化(包括大多数染色体易位)的不利影响实际上可能会被强化治疗更大的细胞减灭作用所抵消。表4总结了当代方案治疗的患者中选定核型发现与治疗结果的关系。在儿童ALL中发现的所有染色体异常中,超二倍体大于50与最有利的预后相关。在另一端,经典Ph+或亚二倍体ALL患者的治疗结果即使在强化化疗方案中也很差;对于这类患者,应考虑采用骨髓移植等替代治疗方法。伴有t(4;11)(q21;q23)的病例临床结果也很差,但不良预后可能仅限于婴儿或青少年年龄组。其他非随机易位,如t(1;19)(q23;p13)和其他几种异常的预后意义,需要在更多患者中进一步评估。最后,随着对这些重排背后分子病理学的了解越来越多,有可能开发出专门针对干扰人类白血病细胞表达的异常基因产物的新型治疗药物。